Sensyne Health plc announced it has signed an agreement with Oxford University to conduct a multi-omics drug discovery research project in asthma. The three-year project will focus on identifying novel drug targets for patients with severe forms of asthma that do not respond to the current standard of care and where pre-existing treatments such as corticosteroids and biologics are less effective. Sensyne will apply its machine learning expertise and proprietary analytical tools to analyse complex genetic, phenotypic, and electronic patient record data sets for the Oxford University 'MultiOmics Project Study Genomics Asthma Project' ("MORSE"). The combination of three data sets will provide a platform for the identification of novel drug targets for the treatment of severe forms of asthma. The IP in any novel drug target identified by this research will be owned by Sensyne Health with a royalty payment back to Oxford University and the Oxford University Hospitals NHS Foundation Trust in line with the Strategic Research Agreements entered into between the parties and Sensyne in 2018. The research will aim to: Undertake whole genome sequencing ("WGS") of highly-phenotyped adult patients with severe forms of asthma from the Oxford Severe Asthma cohort. Data will be compared with controls to identify novel variations associated with specific highly defined asthma phenotypes. Undertake detailed transcriptomic analysis of samples from airways of selected patients who have undergone WGS. Develop a bioinformatic analysis pipeline which can integrate these datasets and provide proof of concept in identifying novel information on pathways and phenotypes. Asthma is the most common chronic lung disease, affecting 350 million people worldwide and causing 400,000 deaths annually. Up to 10% of asthmatics have severe, treatment-refractory disease, constituting a significant unmet clinical need due to exacerbations, healthcare costs and mortality.